Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric National Phase II Trial Assessing TIslelizumab in Monotherapy for Patients With Hepatocellular Carcinoma Child-Pugh B and ALBI Grade 1 or 2 Liver Function Score

NCT05622071 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05622071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05622071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric National Phase II Trial Assessing TIslelizumab in Monotherapy for Patients With Hepatocellular Carcinoma Child-Pugh B and ALBI Grade 1 or 2 Liver Function Score
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2023
Completion date
September 4, 2025
Enrollment
50 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma by bclc stage